4th Induced Proximity-Based Drug Discovery Summit

Conference themes
Whilst PROTACs continue to make headwind, much of the heterobifunctional and monovalent opportunity beyond the ubiquitin proteosome system remains untapped, drawing in new and distinguished biopharma in the race to develop new stabilization, modulation, post-translational modification, and inactivation/activation modalities.

Professional congress organizer (PCO)
Hanson Wade

Notes
URL:
Brochure: https://go.evvnt.com/2313820-3?pid=4832

Speakers: Andrew Zhang, Director, Chemical Biology, AstraZeneca, Brandon Turunen, Co-Founder and Chief Technology Officer, Solu Therapeutics, and more

https://go.evvnt.com/2313820-2?pid=4832

Ms. Isabella Hunter